国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2011年
21期
2591-2594
,共4页
周明%王远东%凌国辉%程国华%韩国栋%邹青峰%王建%谭小军%杨嵘皓%卢家玲
週明%王遠東%凌國輝%程國華%韓國棟%鄒青峰%王建%譚小軍%楊嶸皓%盧傢玲
주명%왕원동%릉국휘%정국화%한국동%추청봉%왕건%담소군%양영호%로가령
肺癌%恩度%化疗%用药时序%凋亡指数
肺癌%恩度%化療%用藥時序%凋亡指數
폐암%은도%화료%용약시서%조망지수
Lung cancer%Rh-Endostatin%Chemotherapy%Treatment sequence%Apoptotic index
目的 观察恩度与化疗联合应用的不同时序对裸鼠A549移植瘤生长和凋亡的影响.方法 60只荷A549人肺癌细胞株移植瘤裸鼠随机分为实验组和对照组,实验组分为I1、D3、D5、D7组,给予恩度治疗并分别在恩度治疗后第1、3、5、7天进行化疗,比较各组裸鼠移植瘤的生长情况和凋亡指数.结果 治疗后第40天各治疗组移植瘤体积均明显小于对照组且差异有极显著性(P<0.01),D3、D5、D7组肿瘤体积小于D1组(P<0.05); D1、D3、D5、D7组凋亡指数分别为(14.28±1.93)、(15.76±1.96)、(15.44±1.91)、(16.55±2.07),与对照组(2.45±0.68)相比差异有极显著性(P<0.01),D3、D5、D7组凋亡指数均高于D1组但仅D7组与D1组比较差异有显著性(P< 0.05); D1、D3、D5、D7组抑瘤率分别为47.97%、46.78%、46.91%、53.52%.结论 在恩度治疗后第3、5、7天给予化疗较恩度与化疗同时给药,有助于促进裸鼠移植瘤细胞凋亡及抑制其生长,恩度治疗后第7天可能是给予化疔的最佳时点.
目的 觀察恩度與化療聯閤應用的不同時序對裸鼠A549移植瘤生長和凋亡的影響.方法 60隻荷A549人肺癌細胞株移植瘤裸鼠隨機分為實驗組和對照組,實驗組分為I1、D3、D5、D7組,給予恩度治療併分彆在恩度治療後第1、3、5、7天進行化療,比較各組裸鼠移植瘤的生長情況和凋亡指數.結果 治療後第40天各治療組移植瘤體積均明顯小于對照組且差異有極顯著性(P<0.01),D3、D5、D7組腫瘤體積小于D1組(P<0.05); D1、D3、D5、D7組凋亡指數分彆為(14.28±1.93)、(15.76±1.96)、(15.44±1.91)、(16.55±2.07),與對照組(2.45±0.68)相比差異有極顯著性(P<0.01),D3、D5、D7組凋亡指數均高于D1組但僅D7組與D1組比較差異有顯著性(P< 0.05); D1、D3、D5、D7組抑瘤率分彆為47.97%、46.78%、46.91%、53.52%.結論 在恩度治療後第3、5、7天給予化療較恩度與化療同時給藥,有助于促進裸鼠移植瘤細胞凋亡及抑製其生長,恩度治療後第7天可能是給予化疔的最佳時點.
목적 관찰은도여화료연합응용적불동시서대라서A549이식류생장화조망적영향.방법 60지하A549인폐암세포주이식류라서수궤분위실험조화대조조,실험조분위I1、D3、D5、D7조,급여은도치료병분별재은도치료후제1、3、5、7천진행화료,비교각조라서이식류적생장정황화조망지수.결과 치료후제40천각치료조이식류체적균명현소우대조조차차이유겁현저성(P<0.01),D3、D5、D7조종류체적소우D1조(P<0.05); D1、D3、D5、D7조조망지수분별위(14.28±1.93)、(15.76±1.96)、(15.44±1.91)、(16.55±2.07),여대조조(2.45±0.68)상비차이유겁현저성(P<0.01),D3、D5、D7조조망지수균고우D1조단부D7조여D1조비교차이유현저성(P< 0.05); D1、D3、D5、D7조억류솔분별위47.97%、46.78%、46.91%、53.52%.결론 재은도치료후제3、5、7천급여화료교은도여화료동시급약,유조우촉진라서이식류세포조망급억제기생장,은도치료후제7천가능시급여화정적최가시점.
Objective To observe the growth and apoptosis effects of human lung carcinoma cell A549 treated in endostar combined with chemotherapy at different sequences.Methods 60 tumorbearing nude mice transplanted with human lung carcinoma cell A549 were randomly divided into experimental group and control group.And experimental group were divided into group D1,D3,D5 and D7,given chemotherapy at 1th,3th,5th and 7th day after recombinant human endostar treatment.The growth change and tumor apoptotic index were compared between the groups after the therapy finished.Results The tumor volume in treatment groups was significantly smaller than that of the control group at 40th day after endostar treatment(P < 0.01):the tumor volume of group D3,D5,D7 were smaller than that of the group D1 (P < 0.05):the apoptotic index of group D1,D5,D3,D7 were (14.28 ± 1.93),(15.76 ± 1.96),(15.44 ± 1.91) and (16.55 ± 2.07) respectively,which were significantly different from those of the control group(AI=2.45 ± 0.68) (P < 0.001); the apoptotic index of group D3,D5,D7 were higher than that of the group D1,but there were significant differences only between group D7 and group D1(P=0.011):the tumor inhibitory rates of group D1,D3,D5,D7s were 47.97%,46.78%,46.91% and 53.52%respectively.Conclusion The effect of chemotherapy given at the 3th,5th,7th day after treatment by endostar to inhibit tumor growth and improve tumor apoptotic index were more effective than those two were given in the same time.Chemotherapy given at the 7th day after endostar treatment could be the best effective point.